人工关节无菌性松动的分子机制及药物干预  

Molecule mechanism of aseptic loosening and drug intervention

作　　者：朱亮亮[1] 赵建宁[1] 

机构地区：[1]南京大学医学院临床学院(南京军区南京总医院)骨科,江苏南京210002

出　　处：《医学研究生学报》2009年第3期320-323,共4页Journal of Medical Postgraduates

基　　金：全军"十一五"重点攻关项目基金资助(批准号:06G043)

摘　　要：人工关节置换广泛用于终末期关节疾病的患者,以改善其生活质量。有部分关节置换患者的假体发生无菌性松动,目前认为,核激活因子受体配体-核激活因子受体-骨保护素-核因子-κB(RANKL-RANK-OPG-NF-κB)系统起着重要的作用。文中就RANKL-RANK-OPG-NF-κB系统如何调控假体周围骨溶解及骨溶解的药物干预进行综述。Joint prosthesis is one of the most successful procedures in orthopaedic surgery and has considerably improved the quality of life for patients affected by terminal joint disease. However, a number of joint prosthesis ultimately failed because of aseptic loosening. There have been major advances in the understanding of aseptic loosening. The RANKL-RANK-OPG-NF-κB system has been shown to play a fundamental role in aseptic loosening. We review how the RANKL-RANK-OPG-NF-κB system regulates aseptic loosening and aseptic loosening drug intervention.

关 键 词：核激活因子受体配体 核激活因子受体 骨保护素 骨溶解 药物干预 

分 类 号：R318.17[医药卫生—生物医学工程]